Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-30T05:43:31.389Z Has data issue: false hasContentIssue false

Metabolic syndrome and vision impairment in postpartum psychosis

Published online by Cambridge University Press:  16 April 2020

A. Pirtovsek Savs
Affiliation:
University Psychiatric Hospital Ljubljana, Ljubljana, Slovenia
M. Derganc
Affiliation:
University Psychiatric Hospital Ljubljana, Ljubljana, Slovenia
V. Svab
Affiliation:
Psychiatric Hospital Ormoz, Ormoz, Slovenia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Metabolic syndrome is an important cause of morbidity among patients with severe mental illnesses. A case of a patient with postpartum psychosis where treatment with olanzapine was followed by vision impairment, metabolic syndrome, and liver dysfunction is presented.

Case report

A 35-year old woman was admitted to our clinic 6 days after delivery. She was convinced that she influenced her baby through the posture of her body, and presented with some other acute psychotic symptoms. She was treated with olanzapine and a good remission of symptoms was achieved. After 2 years the treatment was discontinued and she relapsed. She was treated with olanzapine and she remitted once again. A year later she noticed visual problems. Upon ophthalmologist’s suggestion her blood was tested and the tests revealed elevated blood glucose, liver enzymes, and hyperlipidemia. Olanzapine was immediately discontinued and arypiprazole was introduced, along with oral antidiabetic and hypolipidemic therapy. After a week blood glucose dropped significantly. In the next two months all pathologic lab values were normalized. Hypolipidemic and oral antidiabetic therapy was consequently discontinued. The patient is still taking arypiprazole and she is in good remission.

Conclusion

Increased awareness of risks associated with metabolic syndrome, and optimal monitoring and management are required to minimize cardiovascular and other risk factors associated with the syndrome. Antipsychotic tretment should be chosen very carefully in order to avoid the development or aggravation of metabolic syndrome. In the presented case, metabolic syndrome appeared after years of treatment with olanzapine.

Type
P02-508
Copyright
Copyright © European Psychiatric Association 2011
Submit a response

Comments

No Comments have been published for this article.